Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies
Testing a new combination of anti-cancer drugs in patients newly diagnosed with Ewing sarcoma
Full IRB Study Title:
AEWS2431, Randomized phase 2/3 trial of vincristine-irinotecan-regorafenib in combination with vincristine-doxorubicin-cyclophosphamide (VDC) and ifosfamide-etoposide (IE) in patients with newly diagnosed metastatic Ewing sarcoma
IRB Study ID: 2025-179
Please view complete study details on clinicaltrials.gov
Lead Investigator
Erin Wright, MD
Director, Neuro-Oncology; Director, Shannon E. Wilkes Targeted Therapy Program; Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Co-Director, Neurofibromatosis Clinic; Pediatric Neuro-Oncologist
Pediatric Brain Tumor ProgramShowers Family Center for Childhood Cancer and Blood DisordersNeurofibromatosis (NF) Clinic
